Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-ImmunotherapyReport as inadecuate




Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy - Download this document for free, or read online. Document in PDF available to download.

Journal of Biomedicine and BiotechnologyVolume 2009 2009, Article ID 457936, 13 pages

Research Article

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan

Department of Pathology 1, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan

Division of Pharmaceutical Health Care and Sciences, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan

Department of Chemical Engineering, Faculty of Engineering, Kyushu University, Fukuoka 812-8581, Japan

Department of Biotechnology, School of Engineering, Nagoya University, Nagoya 464-8603, Japan

Department of Chemistry, Fujita Health University School of Health Sciences, Aichi 470-1192, Japan

Department of Cutaneous Sciences, Institute of Dermatology & Cutaneous Sciences, 060-0042, Japan

Received 3 April 2009; Accepted 15 July 2009

Academic Editor: Dominic Fan

Copyright © 2009 Tomoaki Takada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Melanogenesis substrate, N-propionyl-cysteaminylphenol NPrCAP, is selectively incorporated into melanoma cells and inhibits their growth by producing cytotoxic free radicals. Magnetite nanoparticles also disintegrate cancer cells and generate heat shock protein HSP upon exposure to an alternating magnetic field AMF. This study tested if a chemo-thermo-immunotherapy CTI therapy strategy can be developed for better management of melanoma by conjugating NPrCAP on the surface of magnetite nanoparticles NPrCAP-M. We examined the feasibility of this approach in B16 mouse melanoma and evaluated the impact of exposure temperature, frequency, and interval on the inhibition of re-challenged melanoma growth. The therapeutic protocol against the primary transplanted tumor with or without AMF exposure once a day every other day for a total of three treatments not only inhibited the growth of the primary transplant but also prevented the growth of the secondary, re-challenge transplant. The heat-generated therapeutic effect was more significant at a temperature of C than either C or C. NPrCAP-M with AMF exposure, instead of control magnetite alone or without AMF exposure, resulted in the most significant growth inhibition of the re-challenge tumor and increased the life span of the mice. HSP70 production was greatest at C compared to that with C or C. cells were infiltrated at the site of the re-challenge melanoma transplant.





Author:

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents